J Korean Neurol Assoc.  1993 Mar;11(1):85-98.

Open Clinical Trial of Vigabatrin as Add-on Therapy in Severely Intractable Partial Seizures

• Lee BI
• Huh K
• Kim JS
• Park SC
• Sung KM
• Oh KJ

Abstract

Open clinical trial of vigabatrin (VG) as add-on therapy was conducted in 32 patients with severely medically intractable partial seizures with or without secondarily generalized tonic-clonic seizures. Study protocol consisted of 2 months of phase I (VG: 2.0gm/day) and 4 months of phase II(VG: 3.0gm/day and/or 4.0gm/day). During the study period. 9 patients were dropped out due to various reasons :3 patients due to side effects, 1 patient due to side effect and lack of effect, 4 patients for lack of effect and 1 patient due to the development of tuberculous meningitis. At the end of study, improvement greater than 50% reduction of seizure frequency was observed in 12 of 28 patieuts (43%) who did not deuelop seuous side effects. Dizziness was the most frequent side effects found in 10 patients. Psychosis was seen in two patients. Upon long term treatment of VG, about 70% of the patients maintained its beneficial effect. Our study suggests that VG is a new antiepileptic drug useful for severely refractory partial seizures.

MeSH Terms

Dizziness
Humans
Psychotic Disorders
Seizures*
Tuberculosis, Meningeal
Vigabatrin*
Vigabatrin